Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study Logo

What is GRADE?

GRADE is a long-term study of different treatments for type 2 diabetes funded by the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health (NIH). Type 2 diabetes is an epidemic that threatens to become the century's major public health problem and poses enormous human and economic challenges worldwide. Most people with diabetes eventually need 2 medications to control blood glucose levels. A major challenge is to determine which of the many possible drugs is the best choice among people already treated with metformin, the most commonly used diabetes drug. GRADE will determine which combination of two medications is best for glycemic control, has the fewest side effects, and is the most beneficial for overall health.

Eligibility to participate

You may be eligible to participate in the GRADE Study if you:

  • Have type 2 diabetes for 10 years or less
  • Were at least 30 years old at time of diagnosis
  • Are taking no medications for your diabetes or are only taking metformin

This study does not accept healthy participants.
This study is currently following participants.

What is involved in the Study?

  • 2 medications taken daily – metformin and a randomly selected second medication at no charge to participant
  • Blood sugar tested up to 2 times daily at home
  • After an initial period, visits to the University of Minnesota every 3 months until the projected end of the study in 2021.
  • Optional participation in 3 related sub-studies

Principal Investigator

Elizabeth Seaquist, MD


For More Information

Grade Team

grade@umn.edu
(612) 626-0143